Topiramate in the Treatment of Neuropathic Pain in Patients with Cancer

2007 ◽  
Vol 4 (4) ◽  
pp. 241-246 ◽  
Author(s):  
Edmond A. Bendaly ◽  
Carol A. Jordan ◽  
Sandra S. Staehler ◽  
Daniel A. Rushing
Keyword(s):  
Neuropathic Pain ◽  
Patients With Cancer

scholarly journals Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)

2009 ◽  
Vol 17 (4) ◽  
pp. 451-460 ◽  
Author(s):  
Andrea L. Cheville ◽  
Jeff A. Sloan ◽  
Donald W. Northfelt ◽  
Anand P. Jillella ◽  
Gilbert Y. Wong ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Crossover Study ◽  
Phase Iii ◽  
Double Blind ◽  
Patients With Cancer ◽  
Lidocaine Patch ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

Acute pain in cancer

2011 ◽  
Author(s):  
James A. Smart
Keyword(s):  
Neuropathic Pain ◽  
Acute Pain ◽  
Psychological Support ◽  
Interventional Treatment ◽  
Good Place ◽  
Patients With Cancer ◽  
Appropriate Treatment ◽  
Who Pain Ladder

Pain in patients with cancer occurs because of a variety of different causes and has both nociceptive and neuropathic pain components. It is essential that a thorough assessment of the pain is carried out in order to institute appropriate treatment. Whilst the WHO Pain Ladder is a good place to start, there are many other treatments available to treat pain in cancer. Any pharmacological or interventional treatment will be more successful if appropriate psychological support is provided.

Neuropathic Pain in Patients with Cancer

2003 ◽  
Vol 19 (2) ◽  
pp. 115-118 ◽  
Author(s):  
Paolo L. Manfredi ◽  
Gilbert R. Gonzales ◽  
Ribeiro Sady ◽  
Sonja Chandler ◽  
Richard Payne
Keyword(s):  
Neuropathic Pain ◽  
Treatment Options ◽  
Cauda Equina ◽  
Neurological Injury ◽  
Neural Injury ◽  
Patients With Cancer ◽  
Electrophysiological Studies ◽  
Pain Descriptors ◽  
Neurological Injuries ◽  
The Brain

We provide a detailed description of painful neural lesions in hospitalized patients with cancer. A total of 187 consecutive patients with cancer and pain, referred to the pain service of a cancer hospital, were evaluated within 24 hours by two neurologists and followed until discharge or death. Based on history, pain descriptors, physical examination, and radiological and electrophysiological studies, the pain was categorized as neuropathic in 103 patients. The most frequent sites of neurological injury were nerve roots, spinal cord and cauda equina, brachial and lumbosacral plexus, and peripheral nerves. There were no patients with pain caused by injury to the brain. In 93 of these patients, the pain was caused by ongoing neural injury, while, in 10 patients, the neural injury was old and stable. Within these two groups of patients with neuropathic pain, analgesic treatments differed. Prospective studies may determine if categorizing painful neurological injuries in cancer patients based on inferred pathophysiology is useful when deciding among different treatment options.

Tramadol: Does it have a role in cancer pain management?

2005 ◽  
Vol 1 (3) ◽  
pp. 131 ◽  
Author(s):  
Eric E. Prommer, MD
Keyword(s):  
Neuropathic Pain ◽  
Adverse Effects ◽  
Cancer Pain ◽  
Drug Interactions ◽  
Low Dose ◽  
World Health ◽  
Cancer Pain Management ◽  
Patients With Cancer ◽  
The World ◽  
Dual Mechanism

Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization’s guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potential for drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug’s role in cancer care.

An exploratory study on the effectiveness of “Calmare therapy” in patients with cancer-related neuropathic pain: A pilot study

2016 ◽  
Vol 21 ◽  
pp. 1-7 ◽  
Author(s):  
Sang Chul Lee ◽  
Keun Suk Park ◽  
Jee Youn Moon ◽  
Eun Jung Kim ◽  
Yong-Chul Kim ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pilot Study ◽  
Exploratory Study ◽  
Patients With Cancer

Mental health determines the quality of life in patients with cancer-related neuropathic pain in Quito, Ecuador

2017 ◽  
Vol 46 (3) ◽  
pp. 154-160
Author(s):  
Fernando Gordillo Altamirano ◽  
María José Fierro Torres ◽  
Nelson Cevallos Salas ◽  
María Cristina Cervantes Vélez
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Neuropathic Pain ◽  
Patients With Cancer

scholarly journals Assessment of Neuropathic Pain in Patients with Cancer: The Interobserver Reliability. An Observational Study in Daily Practice

2013 ◽  
Vol 6;16 (6;11) ◽  
pp. 569-580
Author(s):  
Hans Timmerman
Keyword(s):  
Neuropathic Pain ◽  
Observational Study ◽  
Clinical Assessment ◽  
Medical Oncology ◽  
Interobserver Reliability ◽  
Daily Practice ◽  
Grading System ◽  
Patients With Cancer ◽  
Level Of Agreement

Background: Neuropathic pain (NeP) is a burdensome problem in all stages of cancer. Although clinical judgment is accepted as a surrogate for an objective gold standard in diagnosing NeP, no publications were found about its reliability. Objectives: Therefore, levels of agreement on the clinical examination of NeP were estimated by calculating kappa-value (Κ) and percentage of pair wise agreement (PA) to determine the interobserver reliability of diagnosing NeP. Setting: The outpatient clinic of medical oncology of the Radboud University Nijmegen Medical Centre. Methods: Patients with cancer with potential NeP complaints were recruited from the outpatient clinic of medical oncology. Physicians were recruited from the department of pain and palliative medicine. Physicians and patients were recruited for participation in an observational study in daily practice. Each patient (N = 34) was examined by 2 specialists via independent clinical assessment. All consultations were video recorded. After each assessment, physicians were asked to indicate the most adequate characterization of the pain: pure NeP, pure nociceptive pain (NoP), mixed pain (MiP), or no pain (NP). Results: Kappa (Κ) for the diagnosis of the most adequate pain characterization was 0.50, PA 64.7%. For diagnosing pure NeP k was 0.78 (PA 91.2%), for the NeP component (NeP + MiP) and NoP component (NoP + MiP), it was respectively 0.52 (PA 76.5%) and 0.61 (PA 82.4%). For the diagnosis on the basis of the grading system between physicians, Κ was 0.34 (PA 52.9%). The intrarater reliability for the diagnosis of an NeP component on the basis of clinical assessment and the NeP component on the basis of the grading system, for pain specialists Κ was 0.69 (PA 85.3%) and for palliative care specialists Κ was 0.61 (PA 79.4%). Limitations: The values of Κ and the PA for the existence of an NeP component are not satisfying and the clinical agreement between physicians around findings from physical examination should encourage a better standardization of the clinical assessment and classification of pain in patients with cancer in respect with the identification of NeP. Conclusions: A substantial level of agreement was found for the diagnosis of pure NeP and a moderate level of agreement for the diagnosis of the NeP component was found, both with a PA ≥ 70%. There was only a fair agreement between the physicians regarding the grading system. However, there was a substantial level of (interrater) agreement for the diagnosis of an NeP component and the outcome of the grading system. The findings in this study also suggest that a better standardization of the clinical assessment and classification of pain in patients with cancer with respect to the identification of neuropathic pain is necessary. Key words: Neuropathic pain, diagnosis, interobserver reliability, agreement, cancer observational study, pain, clinical assessment, diagnostic test

scholarly journals Preliminary Assessment of a Neuropathic Pain Treatment and Referral Algorithm for Patients With Cancer

2011 ◽  
Vol 42 (6) ◽  
pp. 822-838 ◽  
Author(s):  
Ellen M. Lavoie Smith ◽  
Marie A. Bakitas ◽  
Peter Homel ◽  
Mark Piehl ◽  
Linda Kingman ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pain Treatment ◽  
Preliminary Assessment ◽  
Patients With Cancer
Sign in / Sign up

Export Citation Format

Share Document